Very recently, a trial has been started with the aim of testing the clinical efficacy of Bosutinib, a Src/c-Abl inhibitor [26], identified as a candidate molecular target therapy for amyotrophic lateral sclerosis (ALS, OMIM #105400). This evidence concerns the gene ABL1 and amyotrophic lateral sclerosis.